Matthew Roden

Insider Reports History

Location
Cambridge, MA
Signature
/s/ Matthew Roden
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew Roden:

Company Role Class Num Shares Value Price $ Report Date Ownership
Aktis Oncology, Inc. President and CEO, Director Common Stock 91,998 08 Jan 2026 Direct
iTeos Therapeutics, Inc. Director Stock Option (Right to Buy) 17,538 09 Jun 2022 Direct

Insider Reports Filed by Matthew Roden

Symbol Company Period Transactions Value $ Form Type Role Filing Time
AKTS Aktis Oncology, Inc. 08 Jan 2026 0 $0 3 President and CEO, Director 08 Jan 2026, 21:05
ITOS iTeos Therapeutics, Inc. 09 Jun 2022 1 $0 4 Director 10 Jun 2022, 19:56
ITOS iTeos Therapeutics, Inc. 17 Jun 2021 1 $0 4 Director 21 Jun 2021, 20:18